Non-GMO saffron extract enters Asia-Pacific Market
Privately-owned natural ingredients company, Pharmactive Biotech Products, S.L., has launched its all-natural, non-GMO saffron extract, Affron, in the Asia-Pacific market.
Using the Spanish species, Crocus sativus L., was formulated by Pharmactive to enhance the lowest threshold of dosage currently in the market at 28 milligrams per day. This dosage has also been proven to demonstrate pharmacokinetic bio-availability and an absorption time of one-hour.
Pharmactive launched Affron at the recent Vitafoods Asia 2019 held in Singapore on the 25th to 26th of September 2019. A variant of Affron targeted at eye health, Affron EYE, was also one of the finalists for the Nutraingredients Awards Asia in the Field of Healthy Ageing.
Affron is standardized to Lepticrosalides, which is made up of bioactive compounds, safranal and crocin gives Affron its palatable attributes. Based on five clinical studies, Affron has shown to enhance mood and reduce anxiety and depression symptoms. This is also the first saffron extract to be clinically trialed on adolescents.
Pharmactive grows and cultivates the saffron in its fields within the terrain of Castilla-La-Mancha in Spain, where the climate provides optimal conditions for growth of saffron.
“Crocus sativus L. species has been cultivated and consumed for centuries in Spain and its culinary and beneficial values have been long appreciated,” explains Julia Diaz, Marketing Manager of Pharmactive.
“As a high-value botanical, saffron is extremely susceptible to counterfeiting,” adds Alberto Espinel, Head of R&D of Pharmactive. “The company’s saffron is home grown and manufactured in their extraction plant in Madrid. The optimized extraction process employed ensures the highest concentration of saffron’s active Lepticrosalides.”
Its water-soluble nature makes Affron convenient to be included into food and supplements.
Photo credit: Pharmactive Biotech Products, S.L.